ILMN Illumina Inc
XNAS
221.02
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ILMN
$221.02
—
What changed
Recent filings, trades and movesKey stats
$221.02
- 52-Week Range
- $112.65 – $309.35
- YTD
- +64.51%
- IV Rank (30D)
- 55.58
- Straddle Price
- $33.05
- P/C Vol Ratio
- 1.18
- Market Cap
- $32.2B
- Open
- $216.98
- Day Range
- $211.21 – $221.53
- Volume
- 997,177
- Prev Close
- $213.13
Fair Value
MODEL: SHORT
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.23 |
| Cost of Equity (CAPM) | 10.76% (VRP-adj) |
| WACC | 10.82% |
| Volatility Risk Premium | -10.0pp (IV − HV30), ERP adj -25bps |
| Effective Tax Rate | 15.4% |
| Rev. Growth (YoY, DCF input) | +4.2% |
| DCF Horizon | 12 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.04 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $1.1B |
| Return on Equity (TTM) | 28.5% |
| Book / Price | 9.6% |
| Gross Margin (TTM) | 67.9% |
| FCF Margin (TTM) | 23.3% |
| Debt / Equity | 0.57 |
| Quality Score | 4/6 — high quality (12y DCF) |
| Market-Implied Growth | +17.9% (reverse-DCF on current price) |
| SMA 50 | $249.15 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $259.01 |
| Bollinger Width / SMA20 | 37.5% (drives anchor stability) |
| Net Debt | $0.5B |
| Market Cap | $33B |
Peers used for multiples: AMGN, GILD, MRNA, NTRA, NVDA, TWST, TXG, VRTX
60-Day Conviction
31%
20-Day Fair Value
≈ by Dec 8, 2026
$220.95
α -0.2%
rank 24%
conviction
15%
40-Day Fair Value
≈ by Jan 6, 2027
$218.31
α -1.4%
rank 24%
conviction
50%
60-Day Fair Value
≈ by Feb 4, 2027
$218.93
α -1.1%
rank 24%
conviction
31%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $90.25 | 30% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $160.69 | 14% | median 26.5× · 3 peers |
| Peer EV/EBITDA | $213.96 | 14% | median 25.8× · 4 peers |
| Peer P/B | $339.93 | 3% | median 16.6× · 8 peers |
| Peer P/S | $410.18 | 9% | median 13.4× · 8 peers |
| Market Anchor (SMA50) | $249.15 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $212.34 | 30% | 36 strikes · skew +0.22 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- LABORATORY ANALYTICAL INSTRUMENTS (3826) · industry map
- Exchange
- XNAS
- Market Cap
- $32.2B
- Employees
- 8,650
- List Date
- 2000-07-28
- CIK
- 0001110803
- Last Earnings
- Oct 29 after close · −18.6% vs ±13.3% expected
- Next Earnings
- ~Feb 4, 2027 (estimated)
- Headquarters
- San Diego, CA
- Homepage
- https://www.illumina.com
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 15.96% | -8.41% | 6.64% | 3.92% | 1.38% | 7.79% | 4.55% |
| Feb | -0.90% | -8.37% | -8.00% | -4.06% | -32.31% | -4.73% | -9.73% |
| Mar | -13.98% | 5.80% | 17.13% | -2.26% | -5.77% | -7.25% | -1.06% |
| Apr | 2.03% | -18.48% | -10.63% | -7.29% | -1.01% | 0.09% | -5.88% |
| May | 4.98% | -20.40% | -2.80% | -16.36% | 7.49% | 20.02% | -1.18% |
| Jun | 16.14% | -21.62% | -5.83% | 0.98% | 17.66% | 6.95% | 2.38% |
| Jul | 5.33% | 13.42% | 2.14% | 16.21% | 4.65% | 11.75% | 8.92% |
| Aug | -7.27% | -6.48% | -12.72% | 7.40% | 5.60% | 7.81% | -0.94% |
| Sep | -12.40% | -4.90% | -18.51% | 0.12% | -2.91% | 32.13% | -1.08% |
| Oct | 5.12% | 22.21% | -19.80% | 11.75% | 20.81% | -11.19% | 4.82% |
| Nov | -12.35% | -0.48% | -4.42% | -3.75% | 9.55% | -2.36%* | -2.30% |
| Dec | 6.37% | -8.45% | 26.82% | -7.94% | 1.90% | -- | 3.74% |
| Total | 3.12% | -49.28% | -33.61% | -5.59% | 17.14% | 68.92% | 0.12% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $256.22
SMA 50: $249.25
SMA 200: $178.32
Current: $220.98
EMA 12: $238.89
EMA 26: $249.08
MACD: -10.1851 | Signal: -7.5762
BEARISH
ADX (14): 31.76
TREND
+DI: 18.91
−DI: 31.13
Momentum Oscillators
RSI (14): 39.13
NEUTRAL
Stoch %K: 10.13
Stoch %D: 8.48
Williams %R: -82.09
Volume & Volatility
BB Upper: $306.74
BB Lower: $205.70
NEUTRAL
OBV: -32,478,809
Vol SMA 20: 2,350,672
Vol ROC: -25.40%
ATR: $16.24
True Range: $10.32
HV 20: 92.6%
HV 30: 83.9%
HV 60: 71.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before ILMN’s Oct 29 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BULLISH (confidence level: 8/10)
Key Drivers:
- Positive news sentiment from recent headlines highlighting growth in cervical cancer diagnostics, biomarkers, and personalized medicine
- Technical indicators showing a bullish momentum signal from the MACD histogram
Primary Risks:
- High volatility and potential for price movements amplified by market fluctuations
- Options market pricing an expected move of $11.90 by expiration, which may impact investor sentiment
Investment Thesis: ILMN's strong fundamentals in personalized medicine and diagnostics, combined with positive news sentiment, suggest a bullish trend. However, high volatility and market amplification pose risks that should be monitored.
Recent News Sentiment Impact: The recent headlines have created a strongly positive news sentiment, contributing to the overall bullish assessment.
Technical Analysis
Trend Direction: Medium-term (1-3 months): Bullish
Support/Resistance Levels:
- Upper Bollinger Band: $152.97
- Middle Line: $139.47
- Lower Bollinger Band: $125.97
Momentum Signals:
- RSI interpretation: Neutral (62.49)
- MACD signal: Bullish momentum signal from the histogram
- Bollinger Bands position: Squeeze, breakout potential
Volume Analysis: Volume SMA 20: 1655059.15, indicating increasing institutional interest.
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines highlighting growth in cervical cancer diagnostics, biomarkers, and personalized medicine.
Sentiment Assessment: Aggregate news sentiment is positive, contributing to the overall bullish assessment.
Catalyst Identification: Upcoming earnings dates and FDA approvals in the personalized medicine space may drive further price movements.
Market Narrative: The positive news sentiment aligns with the technical signals, supporting a bullish trend.
Risk & Volatility Assessment
Beta Interpretation: Beta: 1.01 (above average), indicating amplification of market movements.
Volatility Regime: Current volatility is above historical levels, posing risks for investors.
Options Market Signals:
- IV Rank: High (83.4%), showing historically high volatility
- Put/Call Volume Ratio: 0.63 (Bullish sentiment)
Downside Protection: Support levels at $125.97 and $139.47 may provide some protection against potential price drops.
Market Context & Positioning
Sector Performance: ILMN is outperforming the broader market, indicating a strong sector presence.
Institutional Activity: Increasing institutional interest, as seen in volume SMA 20, suggests further buying pressure.
Correlation Analysis: R-squared interpretation: 0.26 (low correlation), indicating some independence from market movements.
Relative Valuation: Position within trading range, potentially providing a good entry point for investors.
Key Levels & Action Items
Critical Price Levels:
- Upper Bollinger Band: $152.97
- Middle Line: $139.47
- Lower Bollinger Band: $125.97
Breakout/Breakdown Levels: Technical levels that could trigger significant moves, such as the upper and lower Bollinger Bands.
Time-Sensitive Catalysts: Upcoming earnings dates, FDA approvals, and product launches in personalized medicine may drive further price movements.
Risk Management: Stop-loss levels at $135.47 and position sizing considerations to manage potential risks.
This analysis provides a comprehensive evaluation of ILMN's stock performance, incorporating technical indicators, news sentiment, risk metrics, options activity, and market context. The overall assessment is bullish, driven by positive news headlines and technical momentum signals. However, high volatility and market amplification pose risks that should be monitored.
Generated
News
All ILMN news →
The Close brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Today's guests are Wolfe Research Managing Director, Internet Equity Research Shweta Khajuria, Illumina CEO Jacob Thaysen, FuelCell…
Clinical sequencing demand drives margin expansion and full-year guidance hikes.
Illumina stock crashed Friday, despite beating third-quarter expectations, on tariff confusion and a shaky backdrop for AI-tied tech names. The post Illumina Crashes As Tariffs, AI Woes Eat Into 157% Run-Up appeared first on Investor's Business Daily .
Showing 1–10 of 13
Page 1 of 2
Earnings History
17 of 24 under expected move
Avg Expected Move
8.03%
Avg Actual Move
6.54%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-12 | After-Close | 2.91% | 0.20% | 0.07x | Within |
| 2021-04-05 | After-Close | 3.29% | 7.88% | 2.40x | Exceeded |
| 2021-08-05 | After-Close | 5.48% | 3.58% | 0.65x | Within |
| 2021-11-04 | After-Close | 6.10% | 3.25% | 0.53x | Within |
| 2022-01-11 | After-Close | 5.40% | 2.46% | 0.46x | Within |
| 2022-05-05 | After-Close | 7.75% | 14.63% | 1.89x | Exceeded |
| 2022-08-11 | After-Close | 7.98% | 8.40% | 1.05x | Exceeded |
| 2022-11-03 | After-Close | 7.55% | 5.87% | 0.78x | Within |
| 2023-01-11 | After-Close | 4.95% | 5.05% | 1.02x | Exceeded |
| 2023-04-25 | After-Close | 6.20% | 3.53% | 0.57x | Within |
| 2023-08-09 | After-Close | 7.56% | 0.34% | 0.04x | Within |
| 2023-11-09 | After-Close | 9.89% | 8.05% | 0.81x | Within |
| 2024-01-09 | After-Close | 4.42% | 0.64% | 0.14x | Within |
| 2024-05-02 | After-Close | 7.22% | 4.89% | 0.68x | Within |
| 2024-08-06 | After-Close | 10.18% | 4.07% | 0.40x | Within |
| 2024-11-04 | After-Close | 8.60% | 0.96% | 0.11x | Within |
| 2025-02-06 | After-Close | 8.08% | 9.56% | 1.18x | Exceeded |
| 2025-05-08 | After-Close | 9.05% | 4.80% | 0.53x | Within |
| 2025-07-31 | After-Close | 9.05% | 7.84% | 0.87x | Within |
| 2025-10-30 | After-Close | 14.44% | 24.78% | 1.72x | Exceeded |
| 2026-02-05 | After-Close | 11.11% | 10.40% | 0.94x | Within |
| 2026-04-30 | After-Close | 10.38% | 7.13% | 0.69x | Within |
| 2026-07-30 | After-Close | 11.73% | 0.00% | 0.00x | Within |
| 2026-10-29 | After-Close | 13.34% | 18.64% | 1.40x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
ILMN Options Activity & IV Rank
ILMN IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 57.9%
7-DTE IV: 61.9%
Expected Move: $33.05
7-DTE Move: $19.10
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 1,679
Put Volume: 1,978
P/C Volume: 1.178
NEUTRAL
Call OI: 16,343
Put OI: 11,639
P/C OI: 0.712
Total OI: 27,982
ATM Options Pricing
ATM Call: $17.05
ATM Put: $16.00
Call %: 7.7%
Put %: 7.2%
Chain Summary
Chain Volume: 3,657
Chain OI: 27,982
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 10th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
10%
vs own history
GEX tilt
-0.12
OI-weighted, today
Vanna tilt
+0.21
δ-sensitivity to IV
Charm tilt
-0.08
δ-decay vs time
? What is this?
· 47 ATM contracts, 10k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)84.8HighNov 9
IV Rank (30 DTE)55.6MediumNov 9
Straddle Price (30 DTE)$33.05Nov 9
Beta Analysis
Risk Metrics
Beta: 1.0702
Alpha: 58.47%
Correlation: 0.3038
R-Squared: 9.2%
Stock Volatility: 48.4%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
ILMN Institutional Ownership (13F)
Filings for 2026-09-30
? 13F Guide
Diluted shares outstanding: 153,750,000 (as of 2026-09-27)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
21 filers$308.57M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $61.82M | 20.04% | 2026-06-30 |
| 2 | PEAK6 LLC | $51.31M | 16.63% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $43.64M | 14.14% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $37.25M | 12.07% | 2026-09-30 |
| 5 | Jane Street Group, LLC Custodian | $23.53M | 7.62% | 2026-06-30 |
| 6 | Walleye Trading LLC | $22.68M | 7.35% | 2026-06-30 |
| 7 | Calamos Advisors LLC | $19.59M | 6.35% | 2026-09-30 |
| 8 | Point72 Asset Management, L.P. | $16.25M | 5.27% | 2026-06-30 |
| 9 | Caption Management, LLC | $10.37M | 3.36% | 2026-06-30 |
| 10 | Twin Tree Management, LP | $4.18M | 1.36% | 2026-06-30 |
| 11 | Walleye Capital LLC | $4.04M | 1.31% | 2026-06-30 |
| 12 | GROUP ONE TRADING LLC Custodian | $3.31M | 1.07% | 2026-06-30 |
| 13 | Vontobel Holding Ltd. | $3.01M | 0.98% | 2026-09-30 |
| 14 | Citigroup Inc. Custodian | $2.74M | 0.89% | 2026-09-30 |
| 15 | Simplex Trading, LLC Custodian | $2.38M | 0.77% | 2026-09-30 |
| 16 | Millennium Management LLC Custodian | $914.32K | 0.30% | 2026-06-30 |
| 17 | BNP Paribas Financial Markets Custodian | $879.15K | 0.28% | 2026-06-30 |
| 18 | HUB Investment Partners, LLC | $492.62K | 0.16% | 2026-09-30 |
| 19 | INTEGRITY ALLIANCE, LLC. | $109.47K | 0.04% | 2026-09-30 |
| 20 | Raiffeisen Bank International AG | $49.71K | 0.02% | 2026-09-30 |
| 21 | OSAIC HOLDINGS, INC. Custodian | $25.95K | <0.01% | 2026-06-30 |
18 filers$143.14M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $34.74M | 24.27% | 2026-06-30 |
| 2 | Citigroup Inc. Custodian | $30.10M | 21.03% | 2026-09-30 |
| 3 | IMC-Chicago, LLC Custodian | $22.74M | 15.89% | 2026-09-30 |
| 4 | Citadel Advisors LLC Custodian | $15.90M | 11.10% | 2026-06-30 |
| 5 | Twin Tree Management, LP | $5.49M | 3.83% | 2026-06-30 |
| 6 | Jane Street Group, LLC Custodian | $5.35M | 3.73% | 2026-06-30 |
| 7 | BNP Paribas Financial Markets Custodian | $4.78M | 3.34% | 2026-06-30 |
| 8 | Millennium Management LLC Custodian | $4.36M | 3.05% | 2026-06-30 |
| 9 | Point72 Asset Management, L.P. | $3.62M | 2.53% | 2026-06-30 |
| 10 | PEAK6 LLC | $3.20M | 2.24% | 2026-06-30 |
| 11 | Simplex Trading, LLC Custodian | $3.17M | 2.22% | 2026-09-30 |
| 12 | UBS Group AG Custodian | $2.99M | 2.09% | 2026-06-30 |
| 13 | Walleye Trading LLC | $2.95M | 2.06% | 2026-06-30 |
| 14 | LPL Financial LLC Custodian | $1.92M | 1.34% | 2026-09-30 |
| 15 | Militia Capital Management LLC | $703.32K | 0.49% | 2026-06-30 |
| 16 | GROUP ONE TRADING LLC Custodian | $597.82K | 0.42% | 2026-06-30 |
| 17 | GUARDIAN CAPITAL LP | $307.09K | 0.21% | 2026-06-30 |
| 18 | Walleye Capital LLC | $211.00K | 0.15% | 2026-06-30 |
ILMN Insider Trading (Form 4)
Latest: 2026-11-05Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-05 | Keith A. Meister | Director | Sell (S) | −281,433 | $236.50 | -$66.56M | EDGAR |
| 2026-10-07 | Jacob Thaysen | Chief Executive Officer | Tax (F) | −1,303 | $293.69 | -$382.7K | EDGAR |
| 2026-10-02 | Scott B. Ullem | Director | Award (A) | +113 | $219.80 | $24.8K | EDGAR |
| 2026-10-02 | Keith A. Meister | Director | Award (A) | +107 | $219.80 | $23.5K | EDGAR |
| 2026-09-10 | Julie Ann Coletti | Chief Legal Officer | Award (A) | +18,763 | — | EDGAR | |
| 2026-09-09 | Steven Barnard | SVP, Chief Technology Officer | Tax (F) | −408 | $211.06 | -$86.1K | EDGAR |
| 2026-09-04 | Keith A. Meister | Director | Sell (S) | −263,560 | $217.03 | -$57.20M | EDGAR |
| 2026-08-27 | Keith A. Meister | Director | Sell (S) | −375,941 | $226.74 | -$85.24M | EDGAR |
| 2026-08-21 | Keith A. Meister | Director | Sell (S) | −679,574 | $214.19 | -$145.56M | EDGAR |
| 2026-08-20 | Christensen Jakob Wedel | SVP, Strategy/Corp Development | Sell (S) | −1,033 | $191.52 | -$197.8K | EDGAR |
| 2026-08-07 | Michael C Sullivan | Chief Commercial Officer | Award (A) | +4,503 | $199.87 | $900.0K | EDGAR |
| 2026-08-06 | Keith A. Meister | Director | Sell (S) | −741,127 | $199.91 | -$148.16M | EDGAR |
| 2026-08-03 | Scott M Davies | Chief Legal Officer | Sell (S) | −615 | $200.00 | -$123.0K | EDGAR |
| 2026-07-02 | Scott B. Ullem | Director | Award (A) | +167 | $149.19 | $24.9K | EDGAR |
| 2026-07-02 | Keith A. Meister | Director | Award (A) | +142 | $149.19 | $21.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ILMN Insider Holdings
24 insiders · @ $220.98
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Keith A. Meister | Director | 760,359 | $168.02M | -$657.69M | 15 | 2026-11-05 |
| 2 | Jacob Thaysen | Chief Executive Officer | 107,770 | $23.82M | $1.99M | 12 | 2026-10-07 |
| 3 | Everett Cunningham | SVP, Chief Commercial Officer | 42,614 | $9.42M | $0 | 3 | 2025-07-08 |
| 4 | Steven Barnard | SVP, Chief Technology Officer | 40,927 | $9.04M | $0 | 14 | 2026-09-09 |
| 5 | Ankur Dhingra | SVP, Chief Financial Officer | 34,264 | $7.57M | $495.4K | 4 | 2026-03-09 |
| 6 | Kevin Carl Pegels | Chief of Global Operations | 29,038 | $6.42M | $0 | 17 | 2026-03-09 |
| 7 | Philip W Schiller | Director | 22,220 | $4.91M | $0 | 13 | 2026-05-22 |
| 8 | Robert S Epstein | Director | 22,139 | $4.89M | -$9.58M | 45 | 2025-05-23 |
| 9 | Patricia Leckman | SVP, Chief People Officer | 21,300 | $4.71M | -$529.7K | 11 | 2026-06-09 |
| 10 | Frances Arnold | Director | 20,907 | $4.62M | -$1.20M | 19 | 2025-05-23 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ILMN Board & Officers
As of SEC filings through Nov 5, 2026Directors 10
- Philip W Schiller · since Jul 27, 2016
- Caroline Dorsa · since Jan 26, 2017
- Susan E Siegel · since Feb 5, 2019
- Scott Gottlieb · since Feb 4, 2020
- Scott B. Ullem · since Jun 1, 2023
- Jacob Thaysen · since Sep 25, 2023
- Anna Richo · since May 16, 2024
- Keith A. Meister · since Mar 28, 2025
- David P King · since May 21, 2026
- Daniel Skovronsky · since Jun 16, 2026
Officers 10
- Jacob Thaysen · Chief Executive Officer · since Sep 25, 2023
- Ankur Dhingra · SVP, Chief Financial Officer · since Apr 15, 2024
- Kevin Carl Pegels · Chief of Global Operations · since Nov 2, 2021
- Scott D Ericksen · VP, Chief Accounting Officer · since Oct 16, 2022
- Steven Barnard · SVP, Chief Technology Officer · since Aug 9, 2023
- Patricia Leckman · SVP, Chief People Officer · since Mar 3, 2024
- Scott M Davies · Chief Legal Officer · listed since Mar 2025
- Michael C Sullivan · Chief Commercial Officer · since Jul 20, 2026
- Julie Ann Coletti · Chief Legal Officer · since Aug 3, 2026
- Christensen Jakob Wedel · SVP, Strategy/Corp Development · since Apr 15, 2024
Changes in the last 10 years (63)
| Aug 3, 2026 | Julie Ann Coletti became Chief Legal Officer |
| Jul 20, 2026 | Michael C Sullivan became Chief Commercial Officer |
| Jun 16, 2026 | Daniel Skovronsky became a director |
| May 21, 2026 | David P King became a director |
| Apr 2, 2026 | The company announced the departure of Robert S Epstein from the board in an SEC filing |
| Apr 2, 2026 | The company announced the departure of Gary S Guthart from the board in an SEC filing |
| Apr 2, 2026 | The company announced the departure of Frances Arnold from the board in an SEC filing |
| Jan 4, 2026 | The company announced the departure of Everett Cunningham as SVP, Chief Commercial Officer in an SEC filing |
| Mar 28, 2025 | Keith A. Meister became a director |
| Mar 25, 2025 | The company announced the departure of Stephen P Macmillan from the board in an SEC filing |
| Mar 18, 2025 | The company announced the departure of Carissa Rollins as SVP, Chief Information Officer in an SEC filing |
| Mar 7, 2025 | Scott M Davies listed as Chief Legal Officer (previously Interim General Counsel) in SEC filings |
| Oct 3, 2024 | Scott M Davies became Interim General Counsel |
| Jun 10, 2024 | Everett Cunningham became SVP, Chief Commercial Officer |
| May 16, 2024 | Anna Richo became a director |
| Apr 15, 2024 | Christensen Jakob Wedel became SVP, Strategy/Corp Development |
| Apr 15, 2024 | Ankur Dhingra became SVP, Chief Financial Officer |
| Apr 4, 2024 | The company announced the departure of Joydeep Goswami as SVP Chief Financial Officer in an SEC filing |
| Mar 3, 2024 | Patricia Leckman became SVP, Chief People Officer |
| Sep 25, 2023 | Jacob Thaysen became a director |
| Sep 25, 2023 | Jacob Thaysen became Chief Executive Officer |
| Aug 9, 2023 | The company announced the departure of Phillip G. Febbo as SVP Chief Medical Officer in an SEC filing |
| Aug 9, 2023 | Steven Barnard became SVP, Chief Technology Officer |
| Aug 7, 2023 | The company announced the departure of Alexander Aravanis as SVP, Chief Technology Officer in an SEC filing |
| Jun 11, 2023 | The company announced the departure of Francis A deSouza from the board in an SEC filing |
| Jun 11, 2023 | The company announced the departure of Francis A deSouza as President and CEO in an SEC filing |
| Jun 1, 2023 | Stephen P Macmillan became a director |
| Jun 1, 2023 | Scott B. Ullem became a director |
| May 26, 2023 | Andrew Teno became a director |
| Feb 23, 2023 | Joydeep Goswami listed as SVP Chief Financial Officer (previously SVP Corp Business Development) in SEC filings |
| Oct 16, 2022 | Scott D Ericksen became VP, Chief Accounting Officer |
| Sep 14, 2022 | The company announced the departure of Jose Torres as VP, Chief Accounting Officer in an SEC filing |
| Jun 8, 2022 | The company announced the departure of Sam Samad as SVP and CFO in an SEC filing |
| Apr 18, 2022 | John Edward Frank became Chief Public Affairs Officer |
| Mar 14, 2022 | Carissa Rollins became SVP, Chief Information Officer |
| Nov 2, 2021 | Kevin Carl Pegels became Chief of Global Operations |
| May 24, 2021 | Susan H Tousi listed as SVP, Chief Commercial Officer (previously SVP Product Development) in SEC filings |
| Apr 19, 2021 | Jose Torres became VP, Chief Accounting Officer |
| Sep 28, 2020 | Kathryne Gambrell Reeves became SVP, Chief Marketing Officer |
| Jul 29, 2020 | Mostafa Ronaghi listed as SVP, Entrepreneurial Devlopmt (previously SVP & CTO) in SEC filings |
| Jun 1, 2020 | Alexander Aravanis became SVP, Chief Technology Officer |
| Feb 4, 2020 | Scott Gottlieb became a director |
| Oct 29, 2019 | Susan H Tousi became SVP Product Development |
| Oct 29, 2019 | Phillip G. Febbo became SVP Chief Medical Officer |
| Sep 23, 2019 | Joydeep Goswami became SVP Corp Business Development |
| May 28, 2019 | Karin Eastham reported in an SEC filing no longer being a director |
| Feb 14, 2019 | Omead Ostadan listed as SVP Mktg, Prod & Strat Plan (previously EVP Ops, Products, Strategy) in SEC filings |
| Feb 12, 2019 | Mostafa Ronaghi listed as SVP & CTO (previously Sr VP & CTO) in SEC filings |
| Feb 12, 2019 | Marc Stapley reported in an SEC filing no longer being EVP Strategy & Corp Developmt |
| Feb 5, 2019 | Susan E Siegel became a director |
| Feb 5, 2019 | Charles Dadswell listed as SVP & General Counsel (previously Sr VP & General Counsel) in SEC filings |
| Jan 11, 2019 | Malcolm Garret Hampton listed as SVP Clinical Genomics Group (previously EVP Clinical Genomics Group) in SEC filings |
| Jan 8, 2019 | Sam Samad listed as SVP and CFO (previously Sr. VP and CFO) in SEC filings |
| Jan 1, 2019 | Robert P Ragusa became SVP, Global Quality & Ops |
| Jan 8, 2018 | Aimee L Hoyt became SVP, Chief People Officer |
| Dec 1, 2017 | Gary S Guthart became a director |
| Nov 14, 2017 | Karen K McGinnis became VP, Chief Accounting Officer |
| Oct 30, 2017 | Marc Stapley listed as EVP Strategy & Corp Developmt (previously EVP & Chief Administrative Ofc) in SEC filings |
| May 22, 2017 | Mark Van Oene became SVP Chief Commercial Officer |
| May 3, 2017 | John Wendell Thompson became a director |
| Jan 26, 2017 | Malcolm Garret Hampton became EVP Clinical Genomics Group |
| Jan 26, 2017 | Caroline Dorsa became a director |
| Jan 6, 2017 | Sam Samad became Sr. VP and CFO |
Not reported recently (19)
- Charles Dadswell · Last reported as SVP & General Counsel in an SEC filing dated Sep 17, 2024
- Kathryne Gambrell Reeves · Last reported as SVP, Chief Marketing Officer in an SEC filing dated Mar 7, 2024
- Aimee L Hoyt · Last reported as SVP, Chief People Officer in an SEC filing dated Nov 9, 2023
- Susan H Tousi · Last reported as SVP, Chief Commercial Officer in an SEC filing dated Nov 7, 2023
- Andrew Teno · Last reported as a director in an SEC filing dated May 31, 2023
- John Wendell Thompson · Last reported as a director in an SEC filing dated May 25, 2023
- John Edward Frank · Last reported as Chief Public Affairs Officer in an SEC filing dated May 9, 2023
- Jay T Flatley · Last reported as a director in an SEC filing dated May 20, 2021
- Karen K McGinnis · Last reported as VP, Chief Accounting Officer in an SEC filing dated Feb 22, 2021
- Robert P Ragusa · Last reported as SVP, Global Quality & Ops in an SEC filing dated Feb 18, 2021
- Mostafa Ronaghi · Last reported as SVP, Entrepreneurial Devlopmt in an SEC filing dated Dec 14, 2020
- Mark Van Oene · Last reported as SVP Chief Commercial Officer in an SEC filing dated Nov 9, 2020
- Omead Ostadan · Last reported as SVP Mktg, Prod & Strat Plan in an SEC filing dated May 13, 2020
- Malcolm Garret Hampton · Last reported as SVP Clinical Genomics Group in an SEC filing dated Jan 13, 2020
- A Blaine Bowman · Last reported as a director in an SEC filing dated May 24, 2018
- Michel Bouchard · Last reported as Chief Accounting Officer in an SEC filing dated Nov 7, 2017
- Jeff Huber · Last reported as a director in an SEC filing dated Jun 16, 2017
- Daniel Bradbury · Last reported as a director in an SEC filing dated May 26, 2017
- Christian O Henry · Last reported as EVP & Chief Commercial Officer in an SEC filing dated Jan 31, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ILMN Proposed Insider Sales (Form 144)
Latest: 2026-11-03
? Form 144 Guide
Last 30d:
1 filing
· $87.2M notice value
· Last 90d:
7 filings
· $357.4M notice value
· 2 unique filers
· 14% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Corvex Management LP (6, $357.2M) · JAKOB WEDEL (1, $200K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-11-03 | Corvex Management LP | Affiliate of Director (1) | 369,501 | $87.20M | 2026-11-03 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2026-09-04 | Corvex Management LP | Affiliate of Director (1) | 150,000 | $31.99M | 2026-09-04 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2026-08-27 | Corvex Management LP | Affiliate of Director (1) | 200,000 | $44.97M | 2026-08-27 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2026-08-25 | Corvex Management LP | Affiliate of Director (1) | 300,000 | $66.97M | 2026-08-25 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2026-08-21 | Corvex Management LP | Affiliate of Director (1) | 250,000 | $53.31M | 2026-08-21 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2026-08-20 | Corvex Management LP | Affiliate of Director (1) | 355,000 | $72.78M | 2026-08-20 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2026-08-18 | JAKOB WEDEL | Officer | 1,033 | $199.5K | 2026-08-18 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-04 | Corvex Management LP | Affiliate of Director (1) | 840,000 | $166.45M | 2026-08-04 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2026-07-30 | SCOTT DAVIES | Officer | 615 | $119.8K | 2026-07-30 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-25 | SCOTT DAVIES | Officer | 615 | $107.7K | 2026-06-25 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-10-30
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-10-29 | Earnings results | EDGAR |
| 2026-10-13 | Material agreement · New debt obligation | EDGAR |
| 2026-08-17 | Other events | EDGAR |
| 2026-08-13 | Material agreement · Agreement terminated · New debt obligation | EDGAR |
| 2026-08-12 | Other events | EDGAR |
| 2026-08-07 | Other events | EDGAR |
| 2026-07-30 | Earnings results | EDGAR |
| 2026-06-23 | Director or officer change | EDGAR |
| 2026-05-26 | Shareholder vote results | EDGAR |
| 2026-04-30 | Earnings results · Other events | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-12 | 0001110803-26-000024 | EDGAR |
| 2025-02-12 | 0001110803-25-000019 | EDGAR |
| 2024-02-16 | 0001110803-24-000010 | EDGAR |
| 2023-02-17 | 0001110803-23-000023 | EDGAR |
| 2022-02-18 | 0001110803-22-000013 | EDGAR |
| 2021-02-17 | 0001110803-21-000015 | EDGAR |
| 2020-02-11 | 0001110803-20-000018 | EDGAR |
| 2019-02-12 | 0001110803-19-000013 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-10-30 | 0001110803-26-000207 | EDGAR |
| 2026-07-31 | 0001110803-26-000160 | EDGAR |
| 2026-05-04 | 0001110803-26-000092 | EDGAR |
| 2025-10-31 | 0001110803-25-000073 | EDGAR |
| 2025-08-01 | 0001110803-25-000060 | EDGAR |
| 2025-05-09 | 0001110803-25-000046 | EDGAR |
| 2024-11-06 | 0001110803-24-000052 | EDGAR |
| 2024-08-07 | 0001110803-24-000044 | EDGAR |
| 2024-05-03 | 0001110803-24-000024 | EDGAR |
| 2023-11-13 | 0001110803-23-000086 | EDGAR |
ETF Holders
286 ETFs hold ILMN
25 shown · $6.26B total exposure · 0.09% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.06% | $1.3B | — | 2026-09-30 |
| 2 | VOO Vanguard S&P 500 ETF | Vanguard | 0.06% | $1.1B | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.52% | $930.1M | — | 2026-09-30 |
| 4 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 1.18% | $517.7M | — | 2026-09-30 |
| 5 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.05% | $432.7M | $852.9B | 2026-11-06 |
| 6 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.05% | $385.1M | $777.7B | 2026-11-05 |
| 7 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 2.22% | $242.5M | $11.1B | 2026-11-06 |
| 8 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 0.47% | $233.9M | $49.9B | 2026-11-05 |
| 9 | RSP Invesco S&P 500 Equal Weight ETF | Invesco | 0.20% | $204.1M | — | 2026-11-05 |
| 10 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.24% | $138.4M | $56.9B | 2026-11-06 |
| 11 | VHT Vanguard Health Care ETF | Vanguard | 0.56% | $123.3M | — | 2026-09-30 |
| 12 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.05% | $88.0M | $177.9B | 2026-11-05 |
| 13 | FBT First Trust NYSE® Arca® Biotechnology Index Fund | First Trust | 2.55% | $75.7M | $3.0B | 2026-11-06 |
| 14 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.09% | $71.3M | $82.9B | 2026-11-06 |
| 15 | IWS iShares Russell Mid-Cap Value ETF | iShares (BlackRock) | 0.32% | $46.5M | $14.8B | 2026-11-06 |
| 16 | FMDE Fidelity Enhanced Mid Cap Core ETF | Fidelity | 0.54% | $46.3M | $8.6B | 2026-11-05 |
| 17 | JTEK JPMorgan U.S. Tech Leaders ETF | JPMorgan | 1.13% | $45.4M | $4.0B | 2026-11-06 |
| 18 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.05% | $42.4M | $93.2B | 2026-11-06 |
| 19 | ROBO ROBO Global Robotics and Automation Index ETF | Nport | 1.92% | $38.1M | — | 2026-07-31 |
| 20 | IVW iShares S&P 500 Growth ETF | iShares (BlackRock) | 0.05% | $37.1M | $71.7B | 2026-11-06 |
| 21 | VT Vanguard Total World Stock ETF | Vanguard | 0.04% | $36.4M | — | 2026-09-30 |
| 22 | SCHX Schwab U.S. Large-Cap ETF | Nport | 0.05% | $34.7M | — | 2026-08-31 |
| 23 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.04% | $34.6M | — | 2026-11-05 |
| 24 | MTUM iShares MSCI USA Momentum Factor ETF | iShares (BlackRock) | 0.22% | $34.5M | $15.8B | 2026-11-06 |
| 25 | JEPI JPMorgan Equity Premium Income ETF | JPMorgan | 0.06% | $27.1M | $45.2B | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
38.01
TTM Diluted EPS
$5.82
TTM Revenue
$4.54B
TTM Net Income
$895.00M
TTM Op. Cash Flow
$1.23B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-27 | $1.13B | $220.00M | $1.43 | $419.00M |
| Q1 '26 | 2026-03-29 | $1.09B | $134.00M | $0.87 | $289.00M |
| Q4 '25 | 2025-12-28 | $1.16B | $334.00M | $2.16 | $321.00M |
| Q3 '25 | 2025-09-28 | $1.08B | $150.00M | $0.98 | $284.00M |
| Q2 '25 | 2025-06-29 | $1.06B | $235.00M | $1.49 | $223.00M |
| Q1 '25 | 2025-03-30 | $1.04B | $131.00M | $0.82 | $240.00M |
| Q4 '24 | 2024-12-29 | $1.10B | $187.00M | $1.17 | $364.00M |
| Q3 '24 | 2024-09-29 | $1.08B | $705.00M | $4.42 | $316.00M |
| Q2 '24 | 2024-06-30 | $1.11B | $-1.99B | $-12.48 | $96.00M |
| Q1 '24 | 2024-03-31 | $1.08B | $-126.00M | $-0.79 | $61.00M |
| Q4 '23 | 2023-12-31 | $1.12B | $-175.00M | $-1.11 | $224.00M |
| Q3 '23 | 2023-10-01 | $1.12B | $-754.00M | $-4.77 | $139.00M |
Q3 2026 • period ending 2026-09-27 • filed 2026-10-30
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
38.01
P/B
12.83
P/S
7.82
EV/EBITDA
30.72
EV/Sales
7.91
ROE
31.9%
ROA
13.0%
Div Yield
0.00%
FCF Yield
3.25%
Debt/Equity
0.56
Current Ratio
—
Market Cap
$34.35B
as of 2026-11-09
ILMN vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| NVDA Nvidia Corp | $4.51T | 22.2 | +83.4% | −6.8% | 87 |
| AMGN Amgen Inc | $249.0B | 26.9 | +8.2% | +41.6% | 33 |
| GILD Gilead Sciences Inc | $207.0B | — | +6.5% | +39.4% | 49 |
| VRTX Vertex Pharmaceuticals Inc | $138.7B | 35.4 | +10.5% | +21.6% | 63 |
| MRNA Moderna, Inc. Common Stock | $101.5B | — | −27.6% | +804.8% | 51 |
| NTRA Natera, Inc. Common Stock | $45.1B | — | +36.6% | +39.5% | 44 |
| ILMN Illumina Inc | $32.2B | 38.0 | +5.8% | +64.5% | 56 |
| TWST Twist Bioscience Corporation Common Stoc | $8.0B | — | +17.8% | +320.9% | 99 |
| TXG 10x Genomics, Inc. Class A Common Stock | $7.7B | — | +2.3% | +289.8% | 42 |
| Peer median | $120.1B | 26.9 | +9.3% | +40.6% | 50 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
7.89M
SI % of Float
5.52%
Days to Cover
2.94
Short Vol Ratio
39.0%
Free Float
142.79M
Float %
94.6%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-24